Invitrogen Gets Biotech Patent Win In Jury Trial

Law360, New York (July 26, 2006, 12:00 AM EDT) -- A long-running biotech patent infringement lawsuit between life science companies Invitrogen Corp. and Stratagene Corp. over a patent involving a process of creating competent E. coli cells was brought to a close by a Texas jury’s ruling on Tuesday.

The jury ruled that Invitrogen’s patent is valid and that Stratagene infringed on the patent, and awarded Invitrogen a 15% royalty rate on sales of Stratagene’s competent E. coli cell products between 1997 and 2004 for a total of $7.8 million.

Invitrogen was not entitled to lost...
To view the full article, register now.